Background & Methods: The aim is to study Efficacy of super-bioavailable itraconazole 130 mg and conventional-itraconazole 100 mg twice daily in glabrous tinea infection. Patients with  KOH positive were given itraconazole in two different  formulation. Patient with KOH negative were declared clinically cure.

Results: We found KOH-negative Patient (After treatment) in Group A as super-bioavailable itraconazole 130 mg with 54% whereas Group B as conventional-itraconazole 100mg with 46%. (p=0.271669)

Conclusion: Super-Bioavailable itraconazole 130 mg has better pharmacokinetic profile than conventional itraconazole 100 mg. This may not reflect in the form of better efficacy and safety than in the treatment of dermatophytosis. Multiple other factors might have a role to play in the lack of adequate clinical response of dermatophytosis to itraconazole. We could not find any better efficacy or safety of SB itraconazole as compared to conventional itraconazole.